1. Show article details.

    BRIEF-Acceleron Appoints Christopher Hite To Its Board Of Directors

    Reuters – 5:12 PM ET 06/04/2020

    Acceleron Pharma Inc (XLRN): * ACCELERON APPOINTS CHRISTOPHER HITE TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

  2. Show article details.

    Acceleron Appoints Christopher Hite to its Board of Directors

    Business Wire – 4:05 PM ET 06/04/2020

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Christopher Hite to its Board of Directors. Mr. Hite is currently Executive Vice President and Vice Chairman at Royalty Pharma.

  3. Show article details.

    BRIEF-Acceleron Announces Presentations On Reblozy At 2020 American Society Of Clinical Oncology & European Hematology Association Virtual Annual Meetings

    Reuters – 7:09 AM ET 05/20/2020

    Acceleron Pharma Inc (XLRN): * ACCELERON - ANNOUNCES PRESENTATIONS ON REBLOZY AT 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY & EUROPEAN HEMATOLOGY ASSOCIATION VIRTUAL ANNUAL MEETINGS Source text for Eikon: Further company coverage:

  4. Show article details.

    Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2020 American Society of Clinical Oncology and European Hematology Association Virtual Annual Meetings

    Business Wire – 7:00 AM ET 05/20/2020

    Acceleron Pharma Inc. (XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that a total of six distinct abstracts on REBLOZYL® will be presented at the upcoming 2020 American Society of Clinical Oncology 2020 Virtual Scientific Program, held May 29-31, and at the 25th...

  5. Show article details.

    Acceleron Announces Oral Presentation of PULSAR Phase 2 Trial Results in Virtual American Thoracic Society 2020 Conference Session on June 24, 2020

    Business Wire – 7:00 AM ET 05/19/2020

    Acceleron to host an investor and analyst webcast and conference call following the virtual ATS 2020 presentation on June 24th Acceleron Pharma Inc. (XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that an oral presentation of the PULSAR Phase 2 trial topline resu...

  6. Show article details.

    Acceleron Announces Publication in Science Translational Medicine Describing the Underlying Biology Behind Sotatercept’s Potential as a Novel Therapy in Pulmonary Arterial Hypertension

    Business Wire – 4:01 PM ET 05/13/2020

    Preclinical research of murine version of sotatercept reveals significant role of key TGF-beta superfamily proteins, including activin and growth differentiation factor ligands, in pulmonary vascular disease; points to therapeutic strategy in pulmonary arterial hypertension CAMBRIDGE, Mass.

  7. Show article details.

    Acceleron Reports First Quarter 2020 Operating and Financial Results

    Business Wire – 4:05 PM ET 05/11/2020

    - REBLOZYL®, a first-in-class erythroid maturation agent, was approved by the U.S. FDA to treat anemia in adults with lower-risk myelodysplastic syndromes - - REBLOZYL received positive CHMP opinion for the treatment of adults with transfusion-dependent anemia in lower-risk MDS and beta-thalassemia - - Pivotal Phase 3 MEDALIST and BELIEVE trial results published in New England Journal of Medici...

  8. Show article details.

    Acceleron to Webcast First Quarter 2020 Operating and Financial Results on May 11, 2020

    Business Wire – 7:00 AM ET 05/05/2020

    Acceleron Pharma Inc. (XLRN) today announced it will host a webcast and conference call on Monday, May 11, 2020 at 5:00 p.m. EDT to discuss its first quarter 2020 operating and financial results.

  9. Show article details.

    BRIEF-Acceleron Receives Priority Medicines Designation From European Medicines Agency For Sotatercept In Pulmonary Arterial Hypertension

    Reuters – 8:19 AM ET 05/04/2020

    Acceleron Pharma Inc (XLRN): * ACCELERON RECEIVES PRIORITY MEDICINES DESIGNATION FROM EUROPEAN MEDICINES AGENCY FOR SOTATERCEPT IN PULMONARY ARTERIAL HYPERTENSION Source text for Eikon: Further company coverage:

  10. Show article details.

    Acceleron Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Sotatercept in Pulmonary Arterial Hypertension

    Business Wire – 7:00 AM ET 05/04/2020

    First therapeutic to receive PRIME designation in pulmonary arterial hypertension since the EMA established the program in 2016 PRIME designation comes just three weeks after US FDA granted sotatercept Breakthrough Therapy designation CAMBRIDGE, Mass.

  11. Show article details.

    Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes

    Business Wire – 4:16 PM ET 04/30/2020

    Recommendation for approval based on results from pivotal Phase 3 MEDALIST and BELIEVE studies Bristol Myers Squibb (BMY) and Acceleron Pharma Inc. (XLRN) today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion, recommending the approval of Reblozyl for the treatment of: This CHMP recommendation will now be reviewed by the Europ...

  12. Show article details.

    Acceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial Hypertension

    Business Wire – 7:05 AM ET 04/08/2020

    Sotatercept granted first FDA Breakthrough Therapy designation in pulmonary arterial hypertension since the Agency established the designation in 2012 Acceleron Pharma Inc. (XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Admini...

  13. Show article details.

    Acceleron Announces Retirement of Director Jean George

    Business Wire – 4:05 PM ET 04/07/2020

    Acceleron Pharma Inc. (XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that Jean George is retiring from her position on its Board of Directors.

  14. Show article details.

    BRIEF-Acceleron Pharma & Bristol-Myers Said That U.S. FDA Approved Reblozyl

    Reuters – 9:48 AM ET 04/06/2020

    Bristol-Myers Squibb Co (BMY): * ACCELERON PHARMA INC (XLRN) - ON APRIL 3, CO & BRISTOL-MYERS ANNOUNCED THAT U.S. FDA APPROVED REBLOZYL Source text: https://bit.ly/3aIPiqO Further company coverage:

  15. Show article details.

    U.S. Food and Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt), the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

    Business Wire – 5:08 PM ET 04/03/2020

    The FDA approval marks the second indication for Reblozyl and the first new treatment option in over a decade for patients with MDS who require red blood cell transfusions and have failed an erythropoiesis stimulating agent Reblozyl regulates late-stage RBC maturation to relieve patients from the burden of regular RBC transfusions PRINCETON, N.J. & CAMBRIDGE, Mass.

  16. Show article details.

    New England Journal of Medicine Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia

    Business Wire – 6:59 AM ET 03/26/2020

    Results demonstrate that treatment with Reblozyl provides significant reduction in transfusion burden for patients with beta thalassemia-associated anemia compared to placebo Bristol-Myers Squibb Company (BMY) and Acceleron Pharma Inc. (XLRN) today announced that the New England Journal of Medicine has published results from BELIEVE, the pivotal Phase 3 study evaluating the safety and efficacy of Reblozyl f...

  17. Show article details.

    BRIEF-Acceleron To Discontinue Development Of ACE-083

    Reuters – 4:32 PM ET 03/09/2020

    Acceleron Pharma Inc (XLRN): * ACCELERON ANNOUNCES TOPLINE RESULTS FROM THE PHASE 2 TRIAL OF ACE-083 IN PATIENTS WITH CHARCOT-MARIE-TOOTH DISEASE. * Acceleron Pharma Inc (XLRN) - ACE-083 DID NOT ACHIEVE STATISTICALLY SIGNIFICANT IMPROVEMENTS IN FUNCTIONAL ENDPOINTS RELATIVE TO PLACEBO. * Acceleron Pharma Inc (XLRN) - ACCELERON TO DISCONTINUE DEVELOPMENT OF ACE-083 Source text for Eikon: Further company coverage:

  18. Show article details.

    Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease

    Business Wire – 4:05 PM ET 03/09/2020

    – ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo – – Acceleron to discontinue development of ACE-083 – Acceleron Pharma Inc. (XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment with ACE-083 in...

Page:

Today's and Upcoming Events

  • Aug
    03

    XLRN to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    11

    XLRN announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.